What is Kcentra (prothrombin complex concentrate)?

What is Kcentra?

Kcentra is a four-factor prothrombin complex concentrate (4F-PCC) that contains purified vitamin K-dependent clotting factors (II, VII, IX, and X) plus proteins C and S, derived from pooled human plasma and used primarily for rapid reversal of warfarin anticoagulation in patients with major bleeding or requiring urgent surgery. 1

Composition and Formulation

Kcentra is a lyophilized (freeze-dried) concentrate that contains 1:

• Factor II (prothrombin): 380-800 units per 500-unit vial
• Factor VII: 200-500 units per 500-unit vial
• Factor IX: 400-620 units per 500-unit vial (the lead factor for potency labeling)
• Factor X: 500-1020 units per 500-unit vial
• Protein C: 420-820 units per 500-unit vial
• Protein S: 240-680 units per 500-unit vial
• Small amounts of antithrombin III and heparin
• Human albumin, sodium chloride, and sodium citrate as excipients

The product is virally inactivated through heat treatment (10 hours at 60°C), nanofiltration, and other manufacturing steps, with no confirmed cases of viral transmission reported in post-marketing surveillance 1, 2.

FDA-Approved Indication

Kcentra is FDA-approved specifically for urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonists (VKAs, primarily warfarin) in adult patients with either acute major bleeding OR need for urgent surgery/invasive procedure. 1

Mechanism of Action and Clinical Use

For Warfarin Reversal (On-Label)

Kcentra works by directly replacing the vitamin K-dependent clotting factors that are depleted by warfarin therapy 3:

• Onset of action: 5-15 minutes 4
• Duration of effect: 12-24 hours 4
• Concentration advantage: Contains approximately 25 times the concentration of vitamin K-dependent factors compared to fresh frozen plasma (25 U/mL vs 1 U/mL) 3

Dosing for warfarin reversal is weight and INR-based 3:

• INR 2 to <4: 25 units/kg
• INR 4 to 6: 35 units/kg
• INR >6: 50 units/kg
• Maximum dose: 5,000 units (capped at 100 kg body weight)

Critical caveat: Because factor VII has a short half-life of only 6 hours, you must also administer 5-10 mg of intravenous vitamin K to maintain sustained reversal and prevent rebound coagulopathy 3, 5. Vitamin K should be given by slow IV infusion over 15-30 minutes in 25-50 mL normal saline 3.

Off-Label Use for Direct Oral Anticoagulants (DOACs)

While not FDA-approved for this indication, Kcentra is increasingly used off-label for DOAC-associated bleeding (rivaroxaban, apixaban, edoxaban) when specific reversal agents are unavailable 3, 6:

• Typical off-label dosing: 25-50 units/kg or fixed dose of 2,000 units 6, 7
• Mechanism: Overcomes anticoagulant effects by increasing thrombin generation through provision of high levels of coagulation proteins 6
• Evidence: Pooled analyses show approximately 80% efficacy with thromboembolism rates around 4% 6
• Important limitation: Does NOT neutralize the DOAC molecule itself—it only provides additional clotting factors to overcome the anticoagulant effect 8

The 2020 ACC Expert Consensus states it is reasonable to consider specific reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) over 4F-PCC when available, though no randomized trials directly compare them 3.

Advantages Over Fresh Frozen Plasma

Kcentra offers several practical advantages 3, 9:

• No ABO compatibility testing required—immediately available
• No thawing needed—stored at room temperature as lyophilized powder
• Rapid administration—can be infused in 15-30 minutes vs hours for plasma
• Smaller volume—avoids transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI)
• More predictable and complete INR correction compared to plasma 10

Safety Profile and Thrombotic Risk

Thromboembolism Concerns

The most important safety concern with Kcentra is thromboembolic events (TEEs) 2:

• Post-marketing surveillance data (1996-2022) showed TEEs in approximately 1 per 9,963 standard infusions 2
• Most patients who developed TEEs had pre-existing or concomitant conditions that were significant risk factors for thrombosis 2
• The 2021 ACC/AHA Valvular Heart Disease Guidelines acknowledge this risk but still recommend 4F-PCC as reasonable for mechanical valve patients with uncontrollable bleeding 4

Important context: The thrombotic risk must be weighed against the immediate mortality risk from major bleeding. In patients with life-threatening hemorrhage, the benefit typically outweighs the thrombotic risk 3, 4.

Other Adverse Reactions

• Hypersensitivity reactions: Approximately 1 per 64,485 standard infusions 2
• No confirmed viral transmission in post-marketing surveillance 2
• Overall adverse drug reactions: Approximately 1 per 3,781 standard infusions 2

Clinical Effectiveness Data

Warfarin Reversal

• INR <2 achieved in approximately 89% of patients 7
• Target INR ≤1.3 achieved in 65.8% of patients within median 8 hours 11
• Less than 5% require repeat doses 7

Cardiac Surgery Applications

In specialized populations like ventricular assist device patients undergoing heart transplantation, Kcentra demonstrated 12, 13:

• Significant reduction in blood product requirements (1.76L less total blood volume, 8 fewer units of blood products)
• Faster INR reversal compared to fresh frozen plasma
• No increase in thromboembolic complications in the immediate postoperative period

Fixed-Dose Strategy

Recent data supports fixed-dose protocols (1,500 units for warfarin, 2,000 units for DOACs) as an alternative to weight-based dosing 7:

• Similar efficacy and safety outcomes
• Substantial cost savings: Median $1,567 per patient for warfarin, $3,936 per patient for DOACs
• Annualized hospital savings of $176,239 (warfarin) and $146,733 (DOACs)

Limitations and What Kcentra Does NOT Provide

Critical gap: Kcentra only supplies factors II, VII, IX, and X—it does NOT replace fibrinogen or factor V 9. In patients with major bleeding and coagulopathy from multiple causes (trauma, massive transfusion, dilution), additional hemostatic interventions may be needed.

Administration Considerations

• Standard infusion rate: 0.12 mL/kg/min (approximately 3 units/kg/min), maximum 8.4 mL/min 14
• Emergency situations: Case reports describe successful IV push administration over 20 seconds during cardiopulmonary arrest without immediate thrombotic complications, though this is not standard practice 14
• Monitoring: Check INR 30 minutes after administration to assess degree of correction 5

Bottom Line for Clinical Practice

Kcentra is the preferred agent over fresh frozen plasma for urgent warfarin reversal due to faster onset, smaller volume, and more reliable INR correction. Always co-administer IV vitamin K to prevent rebound coagulopathy. For DOAC-associated bleeding, Kcentra serves as a reasonable off-label option when specific reversal agents are unavailable, though the evidence is less robust. The thrombotic risk is real but relatively low, and in the context of life-threatening bleeding, the benefit typically justifies use.